These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35750335)

  • 1. Therapeutic Effect of Anti-CD52 Monoclonal Antibody in Multiple Sclerosis and Its Animal Models Is Mediated via T Regulatory Cells.
    Kiapour N; Wu B; Wang Y; Seyedsadr M; Kapoor S; Zhang X; Elzoheiry M; Kasimoglu E; Wan Y; Markovic-Plese S
    J Immunol; 2022 Jul; 209(1):49-56. PubMed ID: 35750335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
    J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S3I-201, a selective stat3 inhibitor, ameliorates clinical symptoms in a mouse model of experimental autoimmune encephalomyelitis through the regulation of multiple intracellular signalling in Th1, Th17, and treg cells.
    Ahmad SF; Ansari MA; Nadeem A; Bakheet SA; Al-Mazroua HA; Alomar HA; Al-Hamamah MA; Attia SM
    Mult Scler Relat Disord; 2023 May; 73():104658. PubMed ID: 36989705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8
    Benallegue N; Nicol B; Lasselin J; Bézie S; Flippe L; Regue H; Vimond N; Remy S; Garcia A; Le Frère F; Anegon I; Laplaud D; Guillonneau C
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36266052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S; Pryce G; Giovannoni G; Baker D
    Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAP kinase inhibitor PD98059 regulates Th1, Th9, Th17, and natural T regulatory cells in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.
    Ahmad SF; Ansari MA; Nadeem A; Bakheet SA; Alasmari AF; Shahid M; Al-Mazroua HA; Alomar HA; AsSobeai HM; Alshamrani AA; Attia SM
    Eur J Pharmacol; 2023 Nov; 959():176086. PubMed ID: 37832863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
    Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
    Front Immunol; 2018; 9():3119. PubMed ID: 30687323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of IL-16 in CD4+ T cell-mediated regulation of relapsing multiple sclerosis.
    Skundric DS; Cruikshank WW; Drulovic J
    J Neuroinflammation; 2015 Apr; 12():78. PubMed ID: 25896927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation.
    Esposito M; Ruffini F; Bellone M; Gagliani N; Battaglia M; Martino G; Furlan R
    J Neuroimmunol; 2010 Mar; 220(1-2):52-63. PubMed ID: 20149931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
    Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
    Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivermectin Protects Against Experimental Autoimmune Encephalomyelitis in Mice by Modulating the Th17/Treg Balance Involved in the IL-2/STAT5 Pathway.
    Xie Y; Jin C; Sang H; Liu W; Wang J
    Inflammation; 2023 Oct; 46(5):1626-1638. PubMed ID: 37227550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-mouse CD52 Treatment Ameliorates Colitis through Suppressing Th1/17 Mediated Inflammation and Promoting Tregs Differentiation in IL-10 Deficient Mice.
    Liu J; Wang H; Li Y; Shi P; Gong J; Gu L; Zhu W; Li J
    Biol Pharm Bull; 2018 Sep; 41(9):1423-1429. PubMed ID: 29899181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histamine H4 Receptor Antagonist Ameliorates the Progression of Experimental Autoimmune Encephalomyelitis via Regulation of T-Cell Imbalance.
    Aldossari AA; Assiri MA; Ansari MA; Nadeem A; Attia SM; Bakheet SA; Albekairi TH; Alomar HA; Al-Mazroua HA; Almanaa TN; Al-Hamamah MA; Alwetaid MY; Ahmad SF
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo expanded regulatory T cells CD4
    Lifshitz GV; Zhdanov DD; Lokhonina AV; Eliseeva DD; Lyssuck EY; Zavalishin IA; Bykovskaia SN
    Autoimmunity; 2016 Sep; 49(6):388-396. PubMed ID: 27424664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin B inhibitor alleviates Th1, Th17, and Th22 transcription factor signaling dysregulation in experimental autoimmune encephalomyelitis.
    Ansari MA; Nadeem A; Alshammari MA; Attia SM; Bakheet SA; Khan MR; Albekairi TH; Alasmari AF; Alhosaini K; Alqahtani F; Al-Mazroua HA; Ahmad SF
    Exp Neurol; 2022 May; 351():113997. PubMed ID: 35122866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells.
    Zhang X; Koldzic DN; Izikson L; Reddy J; Nazareno RF; Sakaguchi S; Kuchroo VK; Weiner HL
    Int Immunol; 2004 Feb; 16(2):249-56. PubMed ID: 14734610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo maintenance of human regulatory T cells during CD25 blockade.
    Huss DJ; Mehta DS; Sharma A; You X; Riester KA; Sheridan JP; Amaravadi LS; Elkins JS; Fontenot JD
    J Immunol; 2015 Jan; 194(1):84-92. PubMed ID: 25416807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
    Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
    J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.